You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 21, 2024

Details for Patent: 6,858,596


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,858,596
Title: Formulation containing anti-inflammatory androstane derivative
Abstract:There is provided a pharmaceutical formulation comprising an aqueous suspension of particulate compound of formula (I) ##STR1## or a solvate thereof.
Inventor(s): Biggadike; Keith (Stevenage, GB), Sayani; Amyn Pyarali (Mississauga, CA), Buxton; Ian Richard (Mississauga, CA), Reed; Kenton Lewis (Mississauga, CA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:10/067,020
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery; Use; Composition;
Patent landscape, scope, and claims:

United States Patent 6,858,596: A Detailed Analysis of Scope and Claims

Introduction

United States Patent 6,858,596, titled "Formulation containing anti-inflammatory androstane derivative," is a pharmaceutical patent that describes a specific formulation for an anti-inflammatory medication. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Patent Overview

Publication Number and Authority

The patent, numbered US6858596B2, was issued by the United States Patent and Trademark Office (USPTO)[4].

Prior Art and Background

The patent builds upon prior art related to pharmaceutical formulations, particularly those involving anti-inflammatory compounds. The background section of the patent highlights the need for effective formulations that can deliver anti-inflammatory agents efficiently.

Claims

Independent and Dependent Claims

The patent includes several claims that define the scope of the invention. Here are the key aspects:

  • Independent Claims: These claims stand alone and define the core invention. For example, Claim 1 describes a pharmaceutical formulation comprising an aqueous suspension of a particulate compound of a specific formula (I) or a solvate thereof[4].

  • Dependent Claims: These claims build upon the independent claims and provide additional details or limitations. For instance, dependent claims might specify the particle size range (e.g., between 0.5-10 μm) or the concentration of the active compound (e.g., between 0.005% and 1% w/w)[4].

Scope of the Invention

Pharmaceutical Formulation

The patent describes a pharmaceutical formulation that includes an aqueous suspension of an anti-inflammatory androstane derivative. The formulation is characterized by:

  • Particle Size: The particles of the active compound have a mass mean diameter (MMD) of less than 20 μm, preferably between 0.5-10 μm, and especially around 3-5 μm[4].

  • Suspension Characteristics: The formulation assumes a gel-like appearance at rest due to the thixotropic nature of the suspending agent. This ensures the particulate medicament is dispersed and suspended uniformly[4].

  • Viscosity: The viscosity of the formulation decreases to enable it to flow readily through a spray device, forming a mist that can infiltrate nasal passages. It increases to a sufficient level to resist being cleared by mucociliary forces in the nasal cavities[4].

Patent Landscape

Related Patents and Publications

The patent landscape for pharmaceutical formulations, especially those involving anti-inflammatory agents, is extensive. Other patents and publications may cover similar formulations or different aspects of drug delivery systems.

  • Patent Claims Research Dataset: The USPTO provides datasets that include detailed information on claims from US patents, which can be used to analyze trends and scope in pharmaceutical patents[3].

  • International Patent Applications: The patent references an international patent application (PCT/GB99/04368) that describes a process for preparing the particulate compound, indicating a global context for similar inventions[4].

Legal and Regulatory Considerations

Patentability and Infringement

Patents must meet specific criteria to be considered patentable, such as being novel, non-obvious, and useful. The claims of US6858596B2 must be evaluated against these standards.

  • Section 101 of the Patent Act: This section outlines what can be patented, excluding abstract ideas, laws of nature, and natural phenomena. The claims of this patent must be directed to a patent-eligible subject matter[5].

  • Infringement Litigation: Patent holders must be vigilant about potential infringement. The case of Contour IP Holding LLC v. GoPro, Inc. illustrates the complexities of patent litigation and the importance of claim construction in determining infringement[5].

Economic and Practical Implications

Market Impact

The patent could have significant economic implications for the pharmaceutical industry, particularly in the market for anti-inflammatory medications.

  • Competitive Advantage: Holding a patent for a unique formulation can provide a competitive advantage, allowing the patent holder to dominate a segment of the market[3].

  • Research and Development: The patent could influence research directions, as other companies may need to develop alternative formulations to avoid infringement.

Stakeholder Engagement

Public Comments and Consultations

The process of patenting and enforcing patents often involves stakeholder engagement. For example, the Administrative Conference of the United States (ACUS) has engaged in studies and public comment periods to understand the needs and impacts of patent courts and proceedings[2].

Key Takeaways

  • Unique Formulation: US6858596B2 describes a specific pharmaceutical formulation with detailed characteristics that distinguish it from other anti-inflammatory medications.
  • Patent Scope: The claims define the scope of the invention, including particle size, suspension characteristics, and viscosity.
  • Legal Considerations: The patent must comply with patentability criteria and be defended against potential infringement.
  • Market Impact: The patent could provide a competitive advantage and influence research directions in the pharmaceutical industry.

FAQs

What is the main subject of United States Patent 6,858,596?

The main subject is a pharmaceutical formulation containing an anti-inflammatory androstane derivative.

What are the key characteristics of the formulation described in the patent?

The formulation is an aqueous suspension with particles of a specific size range (0.5-10 μm), a thixotropic suspending agent, and a viscosity that allows it to flow through a spray device and resist clearance by mucociliary forces.

How does the patent landscape affect this invention?

The patent landscape includes related patents and international applications, which can influence the scope and enforcement of the patent.

What legal standards must the claims of this patent meet?

The claims must meet the criteria of novelty, non-obviousness, and usefulness, and must not be directed to abstract ideas, laws of nature, or natural phenomena.

What are the potential economic implications of this patent?

The patent could provide a competitive advantage in the market for anti-inflammatory medications and influence research and development directions in the pharmaceutical industry.

Sources

  1. USPTO Search: https://www.uspto.gov/patents/search
  2. ACUS Study on Small Claims Patent Court: https://www.acus.gov/research-projects/us-patent-small-claims-court
  3. Patent Claims Research Dataset: https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  4. US6858596B2 - Formulation containing anti-inflammatory androstane derivative: https://patents.google.com/patent/US6858596B2/en
  5. CONTOUR IP HOLDING LLC v. GOPRO, INC.: https://cafc.uscourts.gov/opinions-orders/22-1654.OPINION.9-9-2024_2381170.pdf

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 6,858,596

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,858,596

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0019172Aug 05, 2000

International Family Members for US Patent 6,858,596

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1305329 ⤷  Subscribe 91429 Luxembourg ⤷  Subscribe
European Patent Office 1305329 ⤷  Subscribe CA 2008 00022 Denmark ⤷  Subscribe
European Patent Office 1305329 ⤷  Subscribe 300343 Netherlands ⤷  Subscribe
European Patent Office 1305329 ⤷  Subscribe SPC011/2008 Ireland ⤷  Subscribe
European Patent Office 1305329 ⤷  Subscribe 08C0014 France ⤷  Subscribe
European Patent Office 1305329 ⤷  Subscribe C01305329/01 Switzerland ⤷  Subscribe
European Patent Office 1305329 ⤷  Subscribe SPC/GB08/026 United Kingdom ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.